From the "Tell me something I don't already know department"! Coverage denials by payors are the main factor in a dramatic rise in failure to start hepatitis C drug treatment over the past three years, according to new data released March 8 by Trio Health, which has collected real-world evidence on 15,000 HCV patients since the launch of the direct-acting antiviral agents (DAAs) in 2014. As of 2016, more than one-third of patients prescribed DAA treatm
The eradication of hepatitis C may be on the horizon. New, expensive drugs approved by the Ontario government mean new hope for those suffering from liver-destroying hepatitis C, a potentially fatal virus that many people don’t even know they have. The Ontario government has added six new hepatitis drugs to its Ontario Public Drug Programs that will help cure the 40 per cent of hepatitis sufferers who formerly were unable to access treatment. “It’s a v
Friday, February 17, 2017 News Recap HCV & Heart Disease More and more I am hearing that people who have just finished treatment for HCV have had a stroke! Our community really needs to know that hepatitis C is an independent risk factor for various kinds of heart disease: cerebrovascular events (strokes), and ischemic heart disease caused by atherosclerosis (plaque build-up in the arteries – particularly the coronary and carotid arteries, whic...
Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment success and provider satisfaction, according to a presentation at the 2016 AASLD Liver Meeting this month in Boston. The advent of direct-acting antivirals used in interferon-free regimens has made treatment for chronic hepatitis C much more effective. In add
Excellent Article by Dr. James Freeman Hepatitis C, hepatitis B, HIV, TB and malaria are the five major causes of infectious disease death worldwide. In a breakthrough that rivals the invention of penicillin, drugs that cure hepatitis C, with minimal side effects and high success rates, have reached the market, but, in what must be one of the greatest tragedies of modern times, these life-saving medications are not being deployed on a mass scale. Pharm
July 28 is World Hepatitis Day, and it’s fitting to remind ourselves that Canadians’ lives are imperiled unnecessarily by hepatitis C — stemming from a lack of knowledge about the disease and from barriers to gaining access to treatment. New research recently published in the Lancet indicates that "viral hepatitis is a leading cause of death and disability worldwide." In Canada, an estimated 330,000-plus people have been infected by hepatitis C; that’s ...
After a long dry spell, the pharmaceutical research industry has brought to market a spate of innovative treatments that can extend life and often have fewer side effects than older treatments. But these medicines are not affordable to most of the people who need them. Recent treatments for hepatitis C and cancer - both widespread conditions globally - can cost from $50,000 annually to well over $150,000. Amid public outcry, political battles and medi
Punjab becomes the first state in India to provide free treatment to patients diagnosed with Hepatitis C Punjab Chief Minister Parkash Singh Badal has launched a special fund called ‘Mukh Mantri Punjab Hepatitis C Relief Fund’ to provide free treatment for patients affected by Hepatitis C. With this initiative, Punjab has become the first state in the country to provide free treatment to confirmed cases of Hepatitis C, a spokesperson claimed. Punjab
The national hepatitis C treatment programme is to be extended as part of a plan to eliminate the disease in Ireland by 2026, the HSE has announced. The next phase of the strategy will provide an additional 1,500 people with access to life-saving drugs. The directly acting antivirals (DAAs) offer a cure for hepatitis C in the majority of patients. Nearly 700 people have been treated for the infection since late 2014. An estimated 20,000 to 50,000 pe
A state advisory committee recently recommended that Pennsylvania’s Medicaid program pay to treat all patients suffering from hepatitis C — not just those who have advanced or life-threatening cases of the disease. In a 10-7 vote last month, Pennsylvania’s Pharmacy and Therapeutics Committee decided to support a lift on restrictions that keep patients with less-severe cases of hepatitis C from receiving treatment, a constraint intended to reduce costs.